Advancements in Injectable Medications for Opioid Use Disorder Treatment
Treating opioid use disorder (OUD) is evolving as clinicians move toward long-acting injectable medications. These options aim to improve treatment retention and sustain abstinence by reducing the burden of daily dosing. Recent clinical trials are exploring how to initiate these treatments more quickly and whether long-acting formulations outperform standard daily care.
Rapid Initiation of Extended-Release Naltrexone
Naltrexone is an opioid antagonist used to prevent relapse in individuals with OUD. Traditionally, the procedure to start extended-release (XR) naltrexone takes 12 to 14 days. However, new research is testing whether a more accelerated timeline is effective.
A six-site stepped-wedge cluster randomized clinical trial evaluated a rapid 5- to 7-day initiation procedure for injectable XR-naltrexone. This study aimed to determine if patients with active OUD could safely and effectively start the medication in a shorter timeframe compared to the standard two-week protocol.
Comparing Injectable and Oral Buprenorphine
Buprenorphine is another cornerstone of OUD treatment, typically administered as a daily sublingual dose. Researchers are now investigating if a monthly injectable version can provide better outcomes for specific populations, such as Veterans.
The VA-BRAVE trial is currently comparing a 28-day long-acting injectable subcutaneous formulation of buprenorphine (at a target dose of 300mg) against the standard daily sublingual formulation (target dose of 4-32 mg). According to UCSF clinical trial data, this study is tracking 952 Veterans over 52 weeks to determine if the injectable version is superior in:
- Sustaining opioid abstinence.
- Retaining patients in treatment.
- Reducing comorbid substance use and opioid overdoses.
Expanding OUD Treatment in Primary Care
While medications like buprenorphine and injectable naltrexone are effective, access remains a challenge. Many primary care (PC) clinics do not currently offer OUD treatment despite expert recommendations.
The Primary Care Opioid Use Disorders Treatment (PROUD) trial highlights the need to integrate these medications into primary care settings. By making buprenorphine and injectable naltrexone available in PC clinics, healthcare systems can better address the opioid epidemic through more accessible, community-based care.
Key Takeaways for OUD Treatment
- Faster Onboarding: Trials are testing if extended-release naltrexone can be started in 5-7 days instead of the usual 12-14 days.
- Long-Acting Options: Research is comparing 28-day injectable buprenorphine to daily sublingual doses to improve abstinence and retention.
- Increased Access: Efforts are underway to move OUD medication management into primary care clinics to reach more patients.
The Future of OUD Management
The shift toward long-acting injectables represents a significant step in reducing the daily hurdles associated with OUD recovery. By streamlining the initiation process and expanding the locations where these medications are available, the medical community aims to provide more stable, long-term support for those overcoming opioid dependence.
Keep reading